2.47
price up icon6.93%   0.16
after-market アフターアワーズ: 2.48 0.010 +0.40%
loading
前日終値:
$2.31
開ける:
$2.3
24時間の取引高:
13.47M
Relative Volume:
1.66
時価総額:
$515.36M
収益:
$176.23M
当期純損益:
$-257.83M
株価収益率:
-1.7034
EPS:
-1.45
ネットキャッシュフロー:
$-246.00M
1週間 パフォーマンス:
+20.49%
1か月 パフォーマンス:
+26.67%
6か月 パフォーマンス:
+448.28%
1年 パフォーマンス:
+581.57%
1日の値動き範囲:
Value
$2.2501
$2.53
1週間の範囲:
Value
$2.042
$2.84
52週間の値動き範囲:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
名前
Sangamo Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
(510) 970-6000
Name
住所
501 CANAL BLVD., RICHMOND, CA
Name
職員
405
Name
Twitter
@sangamotx
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
SGMO's Discussions on Twitter

SGMO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
2.47 515.36M 176.23M -257.83M -246.00M -1.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 アップグレード Truist Hold → Buy
2024-12-10 繰り返されました H.C. Wainwright Buy
2023-11-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-04-28 ダウングレード BofA Securities Neutral → Underperform
2023-02-27 アップグレード Wedbush Neutral → Outperform
2023-01-06 ダウングレード BofA Securities Buy → Neutral
2022-06-13 再開されました Wedbush Neutral
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-01-07 再開されました Guggenheim Neutral
2021-01-06 開始されました Stifel Hold
2020-12-16 再開されました H.C. Wainwright Buy
2020-09-08 開始されました BofA Securities Buy
2020-07-07 開始されました SunTrust Buy
2019-08-26 開始されました H.C. Wainwright Buy
2018-11-14 ダウングレード JP Morgan Overweight → Neutral
2018-11-09 ダウングレード Guggenheim Buy → Neutral
2018-10-10 開始されました Guggenheim Buy
2018-06-20 開始されました BofA/Merrill Buy
2017-11-15 アップグレード Piper Jaffray Neutral → Overweight
2017-06-22 再開されました Jefferies Buy
2016-11-01 ダウングレード Wedbush Outperform → Neutral
2016-10-19 ダウングレード Piper Jaffray Overweight → Neutral
2015-12-04 開始されました Wells Fargo Outperform
2015-10-23 再開されました Jefferies Buy
2013-05-03 開始されました BioLogic Equity Research Sell
2011-02-23 繰り返されました JMP Securities Mkt Outperform
2010-07-29 繰り返されました Wedbush Outperform
2009-10-19 開始されました Brean Murray Sell
2009-10-07 繰り返されました Leerink Swann Outperform
2009-08-25 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Sangamo Therapeutics Inc (SGMO) 最新ニュース

pulisher
Dec 20, 2024

Astellas and Sangamo sign capsid deal for neurological diseases - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

Astellas partners with Sangamo on cutting-edge gene therapy - The Pharma Letter

Dec 20, 2024
pulisher
Dec 19, 2024

Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development (NASDAQ:SGMO) - Seeking Alpha

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo and Astellas link up in a $1.32B AAV deal - BioWorld Online

Dec 19, 2024
pulisher
Dec 19, 2024

HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap UpHere's What Happened - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo stock gains on Astellas licensing deal (SGMO:NASDAQ) - Seeking Alpha

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo inks $20M gene therapy deal with Astellas; shares rally - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo Shares Rally Premarket on License Deal With Astellas - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 19, 2024
pulisher
Dec 19, 2024

Astellas hopes Sangamo's capsid can get gene therapies across the blood-brain barrier - FirstWord Pharma

Dec 19, 2024
pulisher
Dec 19, 2024

Regarding Sangamo - substack.com

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo Therapeutics, Inc. and Astellas Pharma Inc. Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Marketscreener.com

Dec 19, 2024
pulisher
Dec 19, 2024

Sangamo Therapeutics Lands Major $1.3B Gene Therapy Deal with Astellas for Brain Disease Treatment - StockTitan

Dec 19, 2024
pulisher
Dec 18, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 5%Time to Sell? - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Sangamo surges 24% after Roche ends development of hemophilia A gene therapy - MSN

Dec 17, 2024
pulisher
Dec 17, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap DownShould You Sell? - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.com - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Trading Up 25.5%Still a Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Sangamo shares surge on Roche gene therapy withdrawal By Investing.com - Investing.com Canada

Dec 16, 2024
pulisher
Dec 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces hurdles - Investing.com

Dec 14, 2024
pulisher
Dec 13, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to "Buy" at Truist Financial - MarketBeat

Dec 13, 2024
pulisher
Dec 10, 2024

The Analyst Landscape: 6 Takes On Sangamo Therapeutics - Benzinga

Dec 10, 2024
pulisher
Dec 10, 2024

Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success - TipRanks

Dec 10, 2024
pulisher
Dec 09, 2024

Jacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Dec 09, 2024
pulisher
Dec 08, 2024

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.

Dec 08, 2024
pulisher
Dec 08, 2024

Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30% - Simply Wall St

Dec 08, 2024
pulisher
Dec 06, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Hold Rating by StockNews.com - MarketBeat

Dec 06, 2024
pulisher
Dec 01, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Wasatch Advisors LP - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat

Nov 30, 2024
pulisher
Nov 23, 2024

GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Nov 23, 2024
pulisher
Nov 21, 2024

Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN

Nov 21, 2024
pulisher
Nov 21, 2024

Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online

Nov 21, 2024
pulisher
Nov 20, 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St

Nov 20, 2024
pulisher
Nov 19, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com

Nov 19, 2024
pulisher
Nov 19, 2024

Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 15, 2024
pulisher
Nov 14, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

Sangamo: Q3 Earnings Snapshot - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):